Targeting IL-15 as a therapeutic strategy in organ transplant rejection

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 406-410

  Smith, Xin G ^a   Bolton, Eleanor M ^a   Bradley, J Andrew ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cytokine; IL 15; IL 2; T cell; Transplantation

Indexed keywords

CYCLOSPORIN; CYTOKINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; OKT 4; RECOMBINANT INTERLEUKIN 15 ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ALLOGRAFT; ALLOIMMUNITY; ANTIGEN RECOGNITION; BINDING AFFINITY; CELL DIFFERENTIATION; DNA MODIFICATION; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; NONHUMAN; PHARMACOLOGICAL BLOCKING; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

ANIMALS; GRAFT REJECTION; HUMANS; INTERLEUKIN-15; MICE;

EID: 0036229964     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Permanent survival of organ transplants without immunosuppression: Experimental approaches and possibilities for tolerance induction in clinical transplantation
2. Interleukin 15: Biology and relevance to human disease
3. Structural design and molecular evolution of a cytokine receptor superfamily
4. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor
5. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells
6. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: A role for IL-15 in attraction of T cells
7. Chemoattraction of human blood T lymphocytes by interleukin-15
8. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15
9. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells
10. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation
11. A potential role for interleukin-15 in the regulation of human natural killer cell survival
12. Interleukin 15: What it does and how it is controlled
13. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15
14. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells
15. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells
16. IL-15: A pleiotropic cytokine with diverse receptor / signaling pathways whose expression is controlled at multiple levels
17. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens
18. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13 and IL-15
19. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy
20. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor
21. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
22. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15
23. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells
24. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15
25. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
26. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
27. Control of homeostasis of CD8+ memory T cells by opposing cytokines
28. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans
29. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation
30. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group
31. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group
32. IL-2 knockout recipient mice reject islet cell allografts
33. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection
34. The role of interleukin 15 in T-cell migration and activation in rheumatoid arthritis
35. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
36. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis
37. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis
38. Role of IL-15, IL-2 and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis
39. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology
40. IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS)
41. Intragraft IL-15 transcripts are increased in human renal allograft rejection
42. Increased intragraft IL-15 mRNA expression after liver transplantation
43. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection
44. Interleukin-15 gene transcripts are present in rejecting islet allografts
45. Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression
46. IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies
47. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo
48. Humanized antibody directed to the IL-2 receptor beta chain prolongs primate cardiac allograft survival
49. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival
50. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: Implications for XSCID and XCID
51. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts
52. Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival
53. The sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo
54. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity
55. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection
56. IL-15 and IL-2: A matter of life and death for T cells in vivo